Ion Beam Applications (IOBCF) Stock Price, News & Analysis

Company Overview

Ion Beam Applications (OTCMKTS: IOBCF) is a Belgium-based medical technology company specializing in the development and deployment of particle therapy solutions for cancer treatment. Founded in 1986 and headquartered in Louvain-la-Neuve, the company is best known for its Proteus® line of proton therapy systems, which are designed to deliver precise, high-energy particle beams that target tumors while sparing healthy tissue. IBA oversees the full project lifecycle, from system design and manufacturing to installation, commissioning, and ongoing service support.

In addition to its flagship proton therapy business, IBA operates a diversified portfolio of technologies for medical and industrial applications. Its Radiopharma division supplies cyclotron systems and automated quality control modules used in the production of PET isotopes, enabling advanced diagnostic imaging across hospitals and research centers. The company’s Industrial segment offers e-beam and X-ray irradiation solutions for sterilization, food safety, polymer crosslinking, and wood modification, serving clients in healthcare, food processing, and manufacturing.

Over more than three decades, IBA has installed proton therapy centers and industrial radiation systems in more than 30 countries, with projects spanning Europe, North America, Asia, the Middle East, and Latin America. The company collaborates with leading medical institutions, cancer research centers, and regulatory bodies to advance clinical protocols and improve access to cutting-edge treatments. Strategic partnerships and service agreements help IBA maintain a global footprint and ensure high uptime and performance for its installed base.

Since April 2021, IBA has been led by Chief Executive Officer Javier Garcia Sanz, who has emphasized innovation in compact system design and digital services to support clinical workflows and expand market reach. Looking ahead, the company continues to invest in R&D aimed at reducing treatment costs, improving patient throughput, and exploring novel applications of particle beam technology in oncology and beyond.

Key Stats

• Today's Range: $18.02 to $18.02
• 50-Day Range: $15.00 to $18.02
• 52-Week Range: $11.45 to $19.00
• Volume: 52 shs
• Average Volume: 548 shs
• Market Capitalization: N/A
• P/E Ratio: 212.59
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IOBCF
• CIK: N/A
• Web: www.iba-worldwide.com
• Phone: (321) 047-5811
• Fax: N/A
• Employees: 2,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 212.59
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A